Want to join the conversation?
Biopharmaceutical major $BXLT reported a 14% jump in 1Q16 revenue, but quarterly profit fell on higher costs. The company, focused on hemophilia treatment, reported earnings of $145MM, or $0.21 per share, down from $272MM, or $0.38 per share a year ago. Revenue rose to $1.55Bil. Expenses rose by 36%.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!